| 1554 |
National Cancer Institute |
Html |
en |
Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia. |
| red blood cells | 0.517668 |
| cancer treatment | 0.431205 |
| malignant tumor cells | 0.395015 |
| blood -forming cells | 0.386238 |
| body | 0.377277 |
| PDQ cancer information | 0.428983 |
| clinical trial search | 0.381057 |
| white blood cells | 0.437124 |
| clinical trials | 0.679889 |
| mature blood cells | 0.419721 |
| Natural killer cells | 0.383894 |
| cancer information summary | 0.40184 |
| clinical trial | 0.489229 |
| lymphocytes | 0.390185 |
| Lymphoblastic Leukemia Treatment | 0.406769 |
| Myeloid Leukemia Treatment | 0.391192 |
| blood cells | 0.552101 |
| immature cells | 0.367988 |
| treatment clinical trial | 0.370422 |
| IgVH gene mutation | 0.385864 |
| Cell Leukemia Treatment | 0.388308 |
| NCI PDQ cancer | 0.372246 |
| lymph nodes | 0.416068 |
| Treatment Editorial Board | 0.376334 |
|
| radiation therapy | 0.372299 |
| tyrosine kinase inhibitor | 0.394203 |
| treatment | 0.577005 |
| stored stem cells | 0.374171 |
| myeloid stem cell | 0.372796 |
| immature blood cells | 0.385722 |
| cancer cells | 0.498635 |
| lymphoid stem cell | 0.371902 |
| specific cancer cells | 0.395788 |
| Lymphocytic Leukemia Treatment | 0.392931 |
| treatment clinical trials | 0.392666 |
| Acute Lymphoblastic Leukemia | 0.387556 |
| blood stem cells | 0.421035 |
| National Cancer Institute | 0.439036 |
| normal cells | 0.375452 |
| new treatment | 0.432006 |
| bone marrow | 0.466319 |
| chronic lymphocytic leukemia | 0.905376 |
| cells | 0.56649 |
| cancer clinical trials | 0.397834 |
| cancer | 0.596361 |
| Myelogenous Leukemia Treatment | 0.383031 |
| standard treatment | 0.368392 |
| Leukemia Treatment | 0.421626 |
|
CLICK HERE |
| 1623 |
National Cancer Institute |
Html |
null |
Gonzalez Regimen (PDQ®)–Health Professional Version |
The Gonzalez regimen is a specialized diet that uses enzymes, supplements, and other factors in cancer management based on a theory that involves the use of pancreatic enzymes to help the body get rid of toxins that lead to cancer. Read about existing clinical data in this expert-reviewed summary. |
|
|
CLICK HERE |
| 1777 |
National Cancer Institute |
Html |
es |
El dolor y el cáncer (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del dolor como una complicación a causa del cáncer o su tratamiento. Se tratan abordajes para el control y el tratamiento del dolor relacionado con el cáncer. |
| Moderate Cancer Pain | 0.337641 |
| among patients with | 0.313833 |
| Curr Pain Headache | 0.353041 |
| Palliat Nurs | 0.30942 |
| Chronic Pain Syndromes | 0.356907 |
| Breakthrough Pain Study | 0.329475 |
| Pain Questionnaire | 0.327384 |
| Jensen MP | 0.310829 |
| Cancer Therapy | 0.30947 |
| with breast cancer | 0.313155 |
| Edmonton Symptom Assessment | 0.309493 |
| Pain Terms | 0.351866 |
| pain management | 0.434176 |
| Natl Cancer Inst | 0.310759 |
| Hui D | 0.310443 |
| pain syndromes | 0.398674 |
| Faces Pain Scale | 0.329845 |
| Pain Res | 0.344114 |
| patients with | 0.479951 |
| Pain Symptom Manage | 0.524062 |
| Pain Experience among | 0.326556 |
| Pain Management Nursing | 0.328639 |
| chronic pain | 0.526592 |
| dolor).¿El dolor | 0.346176 |
| Oncol Nurs Forum | 0.309327 |
|
| peor dolor | 0.357775 |
| pain assessment | 0.342098 |
| Care Cancer | 0.331083 |
| breakthrough pain | 0.366572 |
| palliative care | 0.309739 |
| Hosp Palliat Care | 0.329839 |
| Faces Pain | 0.365306 |
| Pain related | 0.328906 |
| pain assessment toolkit | 0.327388 |
| pain control | 0.351552 |
| patients with depression | 0.30909 |
| Brief Pain Inventory | 0.377512 |
| Pain Headache Rep | 0.352431 |
| cancer pain | 0.974628 |
| cancer pain prognostic | 0.363979 |
| pain experience | 0.342944 |
| Clin Oncol | 0.363176 |
| Palliat Med | 0.324432 |
| pain's interference with | 0.332203 |
| breast cancer | 0.321556 |
| Bruera E | 0.316817 |
| edmonton staging system | 0.310908 |
| systematic review | 0.31986 |
| Faces Pain Scale-Revised | 0.327413 |
|
CLICK HERE |
| 1933 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de seno (mama) en el embarazo (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de cáncer de seno (mama) en el embarazo. |
| estadio lllC | 0.545921 |
| procedimientos quizás | 0.519027 |
| estadio iv | 0.622294 |
| siguientes aspectos | 0.528664 |
| secciones llamadas lóbulos | 0.542754 |
| estadio lllB | 0.547235 |
| estadio lllA | 0.548629 |
| estadios ia | 0.51696 |
| ganglio linfático centinela | 0.983407 |
| Oncotype DX | 0.522717 |
| rayos x | 0.518956 |
| estadio ib | 0.594193 |
| prueba ayuda | 0.551927 |
| estadio ia | 0.593122 |
| pezón afección | 0.529911 |
| enlace drugs approved | 0.522117 |
| mama.ampliar cirugÃa | 0.515861 |
| causó hinchazón | 0.517244 |
| National Cancer Institute | 0.51629 |
| cuántos genes | 0.520169 |
|
| siguientes riesgos | 0.513473 |
| realidad células | 0.541214 |
| Instituto Nacional | 0.528985 |
| cuáles lesiones | 0.51826 |
| estadio iiia | 0.547361 |
| PDQ Tratamiento | 0.523188 |
| estadio iiic | 0.745067 |
| cáncer.ampliar mamografÃa | 0.525478 |
| estadio iia | 0.550898 |
| estadio llB | 0.548944 |
| estadio llA | 0.550289 |
| cuánta proteÃna | 0.522295 |
| siguientes casos | 0.520535 |
| Physician Data Query | 0.558856 |
| carcinoma lobulillar | 0.602006 |
| siguientes partes | 0.548502 |
| Breast Cancer | 0.511799 |
| mamas.ampliar carcinoma lobulillar | 0.536157 |
| siguientes pruebas | 0.564002 |
| vasos sanguÃneos | 0.630183 |
|
CLICK HERE |
| 1955 |
National Cancer Institute |
Html |
es |
Tratamiento de la micosis fungoide (incluso el síndrome de Sézary) (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de la micosis fungoide (incluso el síndrome de Sézary). |
| siguientes procedimientos | 0.303227 |
| células madre | 0.320527 |
| estadio iv | 0.313697 |
| La micosis fungoide | 0.416261 |
| llamada terapia | 0.301315 |
| Estadio IIA | 0.301756 |
| vÃa oral | 0.300639 |
| Estadio IIB | 0.301746 |
| rayos x | 0.300779 |
| estadio ivb | 0.303346 |
| estadio ib | 0.303433 |
| enlace drugs approved | 0.306299 |
| estadio ia | 0.303396 |
| radioterapia ultravioleta | 0.303448 |
| micosis fungoide | 0.995318 |
| célula madre mieloide | 0.305243 |
| células t | 0.307128 |
| madre sanguÃneas maduras | 0.302125 |
| luz solar | 0.300631 |
| estadio iva | 0.303278 |
|
| quimioterapia sistémica | 0.305438 |
| National Cancer Institute | 0.300622 |
| Instituto Nacional | 0.301086 |
| célula madre linfoide | 0.305924 |
| PDQ Tratamiento | 0.301318 |
| partÃculas minúsculas | 0.300672 |
| presente sección | 0.300525 |
| llamada fotoquimioterapia | 0.300664 |
| Physician Data Query | 0.302237 |
| Non-Hodgkin Lymphoma | 0.303589 |
| estadio iii | 0.306895 |
| lesiones cutáneas | 0.300795 |
| radiación ultravioleta a | 0.301198 |
| célula madre | 0.319745 |
| luz ultravioleta | 0.30088 |
| ósea elabora células | 0.304191 |
| radiación ultravioleta | 0.315951 |
| Sézary recidivantes | 0.302362 |
| siguientes sumarios | 0.301672 |
| siguientes pruebas | 0.301109 |
|
CLICK HERE |
| 3446 |
National Cancer Institute |
Html |
es |
Consumo de cigarrillo: riesgos para la salud y cómo dejar de fumar (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre la investigación y pautas que se enfocan en la prevención y el abandono del tabaquismo. |
| efectos secundarios comentarios | 0.501986 |
| leucemia mieloide | 0.427415 |
| metabolitos carcinógenos | 0.42791 |
| bupropión marca dosis | 0.454219 |
| grupo vareniclina | 0.463468 |
| importancia clÃnica | 0.450606 |
| MVL Nicorette DS | 0.439222 |
| pruebas directas | 0.619014 |
| MVL Nicoderm CQ | 0.440426 |
| MVL Commit | 0.42718 |
| Sin embargo | 0.467903 |
| muertes prematuras | 0.469229 |
| largo plazo | 0.764238 |
| cessation interventions among | 0.449671 |
| Lung Health Study | 0.44169 |
| Lancaster T | 0.545862 |
| defunciones prematuras | 0.434559 |
| bupropión mejora | 0.45245 |
| Stead LF | 0.482703 |
| orientación mejora | 0.429664 |
| bupropión ap | 0.446903 |
| Nicotine replacement therapy | 0.444158 |
| semanas insomnio | 0.443481 |
| vareniclina mejora | 0.477582 |
| Estados Unidos | 0.989049 |
|
| polacrilex marca dosis | 0.434801 |
| insomnio riesgo | 0.427937 |
| smoking cessation | 0.872626 |
| salud pública | 0.590985 |
| Database Syst Rev | 0.689429 |
| abandono gradual versus | 0.477395 |
| nicotina marca dosis | 0.473496 |
| beneficio hipotético implÃcito | 0.443214 |
| Treating Tobacco Use | 0.44172 |
| versus trn | 0.451335 |
| MVL Nicorette | 0.462807 |
| mejores tasas | 0.435725 |
| Community Intervention Trial | 0.530278 |
| Marca Dosis Efectos | 0.591077 |
| alta calidad | 0.516955 |
| efectos secundarios advertencias | 0.436485 |
| compuestos carcinógenos | 0.426773 |
| tasas promedio | 0.433836 |
| aductos carcinógenos | 0.42846 |
| planta cytisus laburnum | 0.434664 |
| antidepresivo bupropión | 0.449342 |
| cuello uterino | 0.576293 |
| MVL Nicotrol | 0.425887 |
| Surveillance Modeling Network | 0.440037 |
|
CLICK HERE |
| 3528 |
National Cancer Institute |
Html |
es |
Dosis altas de vitamina C (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de dosis altas de vitamina C como tratamiento para personas con cáncer. |
| Natl Acad Sci | 0.417663 |
| ascorbic acid with | 0.319941 |
| Toxicol In Vitro | 0.313376 |
| Sin embargo | 0.355085 |
| exhibit antitumoral effects | 0.313224 |
| Pauling L | 0.325518 |
| Vitamin C | 0.326615 |
| vitamina c | 0.479277 |
| ascorbate enhanced chemosensitivity | 0.326919 |
| Instituto Nacional | 0.312833 |
| Cancer Res | 0.390148 |
| Chen Q | 0.342148 |
| patients with advanced | 0.354811 |
| supportive treatment | 0.331337 |
| Pharmacologic concentrations | 0.313247 |
| In vitro screening | 0.313326 |
| Med Oncol | 0.314224 |
| acid combination therapy | 0.340469 |
| with ascorbic acid | 0.337638 |
| Padayatty SJ | 0.360813 |
| Levine M | 0.40315 |
| patients with | 0.414812 |
| administración iv | 0.317377 |
| ascorbic acid | 0.947894 |
| estadio iv | 0.317436 |
|
| Pharmacologic doses | 0.312587 |
| voluntarios sanos | 0.317063 |
| intravenous ascorbic acid | 0.330687 |
| Proc Natl Acad | 0.418979 |
| benefit patients with | 0.32288 |
| Biol Blood Marrow | 0.314132 |
| acid therapy | 0.32123 |
| relapsed or refractory | 0.319928 |
| Nutr Cancer | 0.315186 |
| parenteral ascorbate enhanced | 0.327964 |
| National Cancer Institute | 0.323649 |
| ácido ascórbico iv | 0.317065 |
| Transl Med | 0.334599 |
| Intern Med | 0.343771 |
| Chemother Pharmacol | 0.319656 |
| Espey MG | 0.344722 |
| Sun AY | 0.318432 |
| Moertel CG | 0.319183 |
| Chem Biol Interact | 0.340687 |
| phase ii | 0.326203 |
| in vitro | 0.345448 |
| high-dose vitamin | 0.327502 |
| High-dose parenteral ascorbate | 0.330109 |
| ascorbic acid induces | 0.316289 |
|
CLICK HERE |
| 3573 |
National Cancer Institute |
Html |
en |
Immunotherapy: Using the Immune System to Treat Cancer |
Immunotherapies are treatments that restore or enhance the immune system’s natural ability to fight cancer. In just the past few years, the rapidly advancing field of cancer immunology has produced several new methods of treating cancer that increase the strength of immune responses against tumors. |
| abnormal cells | 0.352853 |
| CAR T cells | 0.324531 |
| cancer cells | 0.817652 |
| immune system activity | 0.227645 |
| immune responses | 0.409806 |
| toxic substance | 0.204832 |
| dendritic cells | 0.272111 |
| immune system molecules | 0.223265 |
| white blood cells | 0.307219 |
| activated T cells | 0.296761 |
| immune system—research | 0.253725 |
| immune response | 0.250155 |
| advanced lung cancer | 0.212796 |
| cancer treatment vaccine | 0.201283 |
| clinical trials | 0.278634 |
| tumor cells | 0.49599 |
| CD20-expressing cells | 0.269956 |
| normal cells | 0.295119 |
| human clinical trials | 0.248944 |
|
| antibody-dependent cell-mediated cytotoxicity | 0.250246 |
| patients | 0.23385 |
| advanced melanoma | 0.22903 |
| immune cells | 0.680701 |
| immune checkpoint inhibitors | 0.313495 |
| FDA-approved checkpoint inhibitors | 0.216978 |
| therapeutic antibodies | 0.216622 |
| cancer cell death | 0.250231 |
| immunotherapy uses proteins | 0.212508 |
| CAR T-cell therapy | 0.397055 |
| natural killer cells | 0.304861 |
| lymphoma cells | 0.266327 |
| cells | 0.903811 |
| different checkpoint protein | 0.207351 |
| modified T cells | 0.282987 |
| immune checkpoint proteins | 0.3798 |
| existing T cells | 0.321978 |
| certain immune cells | 0.38886 |
|
CLICK HERE |
| 3889 |
National Cancer Institute |
Html |
en |
Parents Who Have a Child with Cancer |
Practical information for parents, when a child has cancer. Tips to help kids and parents cope and stay strong, together with answers to commonly asked questions from parents and children. |
| questions | 0.35493 |
| child life specialist | 0.386505 |
| child’s treatment | 0.35347 |
| child stay | 0.349619 |
| professional help | 0.33179 |
| health care team | 0.725323 |
| integrative medicine | 0.336877 |
| School-aged children | 0.334822 |
| illness children | 0.331523 |
| children | 0.600994 |
| social worker | 0.38279 |
| young children | 0.353967 |
| talk | 0.366273 |
| guide | 0.345294 |
| social media site | 0.334677 |
| individualized education plan | 0.336753 |
| Older children | 0.332601 |
| Child Fights | 0.345493 |
| child’s diagnosis | 0.353024 |
| child react | 0.353407 |
| physical changes | 0.337307 |
| friends | 0.368904 |
| child | 0.906189 |
| parents | 0.404038 |
| treatment | 0.408118 |
|
| Childhood Cancer section | 0.347255 |
| emotional changes | 0.3435 |
| mental health specialist | 0.336601 |
| Children’s Hospital | 0.33095 |
| Stay Strong section | 0.335513 |
| ways | 0.385896 |
| Integrative medicine practices | 0.335837 |
| hospital | 0.356973 |
| social media | 0.340134 |
| people | 0.356129 |
| primary care doctor | 0.338718 |
| way | 0.329858 |
| doctor | 0.358256 |
| child play | 0.355719 |
| school your child | 0.347225 |
| social media sites | 0.338017 |
| new medical information | 0.336758 |
| cancer | 0.500444 |
| information | 0.37152 |
| suggestions | 0.340134 |
| time | 0.433424 |
| family | 0.348424 |
| difficult time | 0.340015 |
| medical situation | 0.335063 |
|
CLICK HERE |
| 16256 |
National Cancer Institute |
Html |
en |
Áreas de investigación |
Sostener un progreso contra el cáncer requiere que se avance a través del continuo de investigación. Entérese de lo extenso que es el trabajo del NCI y de los programas que apoya el instituto para hacer avanzar la investigación oncológica. |
| National Cancer Institute | 0.966549 |
|
|
CLICK HERE |